Protocol: BPC-157 250500 mcg daily SC + CJC-1295/Ipamorelin 100 mcg each at bedtime SC
As one pharmaceutical review noted, "the activation of pro-migratory signals and pro-angiogenic factors by BPC-157 is a double-edged sword." No studies have proven that BPC-157 causes cancer, but the biological plausibility of this concern cannot be dismissed
BPC-157 peptide therapy may be suitable for adults seeking relief from musculoskeletal pain or injuries, joint concerns, digestive issues, chronic inflammation, or central nervous system (CNS) disorders.8 11 It could also potentially be used for neuroprotection, nerve regeneration, repairing organ damage from substance overdoses, healing lesions, and more.7 However, its again important to reiterate that nearly all of the above potential benefits of BPC-157 have not been demonstrated in human studies or trials
A 5 mg retatrutide vial with 2.5 mL of bacteriostatic water makes 2 mg/mL, where 1 mg draws 50 units and 2 mg draws 100 units
xx, Rory